Pamela Hu, MD

Hu P, Samuels S, Sharifi M. Overview of the Treatment of Pediatric Obesity and the 2023 Clinical Practice Guidelines. Pediatric Clinics Of North America 2024 DOI: 10.1016/j.pcl.2024.06.005.

Samuels S, Chajecki A, Hu P, Kayser M, Weyman K, Pan B, Brown E, Van Name M, Wolf R. Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obesity And Metabolism 2024, 26: 1305-1313. PMID: 38229444, DOI: 10.1111/dom.15430.

SAMUELS S, CHAJECKI A, HU P, KAYSER M, WEYMAN K, PAN B, BROWN E, VAN NAME M, WOLF R. 1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis. Diabetes 2023, 72 DOI: 10.2337/db23-1100-p.

Slusher A, Hu P, Samuels S, Tokoglu F, Lat J, Li Z, Alguard M, Strober J, Vatner D, Shabanova V, Caprio S. Rising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States. Obesity 2023, 31: 1383-1391. PMID: 36694381, PMCID: PMC10186584, DOI: 10.1002/oby.23728.

Samuels S, Hu P, Maciejewski K, Li F, Dziura J, Savoye M, Sharifi M. Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity. Obesity 2022, 31: 203-213. PMID: 36502287, PMCID: PMC9780185, DOI: 10.1002/oby.23627.

Hu P, Samuels S, Maciejewski KR, Li F, Aloe C, Van Name M, Savoye M, Sharifi M. Changes in Weight-Related Health Behaviors and Social Determinants of Health among Youth with Overweight/Obesity during the COVID-19 Pandemic. Childhood Obesity 2021, 18: 369-382. PMID: 34919458, PMCID: PMC9492789, DOI: 10.1089/chi.2021.0196.